Molecular Studies and Clinical Correlations in Human Prostatic Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00578240

Recruitment Status : Active, not recruiting

First Posted : December 21, 2007

Last Update Posted : August 25, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Rockefeller University

Flinders Medical Centre

University of Southern California

Gen-Probe, Incorporated

Genentech, Inc.

General Electric

Purdue University

Biocept, Inc.

Duke University

Ikonysis

Array Genomics

Cold Spring Harbor Laboratory

Nodality

Epic Sciences

Rutgers Cancer Institute of New Jersey

Dana-Farber Cancer Institute

Johns Hopkins University

M.D. Anderson Cancer Center

Oregon Health and Science University

University of California, San Francisco

University of Chicago

University of Michigan

University of Washington

University of Wisconsin, Madison

Fred Hutchinson Cancer Center

Broad Institute

Weill Medical College of Cornell University

Institute of Cancer Research, United Kingdom

Vitatex Inc.

Serametrix Corporation

Promega Corporation

Creatv Microtech, Inc.

Viatar LLC

Massachusetts Institute of Technology

Advanced Cell Diagnostics

ApoCell, Inc.

Beckman Coulter GmbH

Bioview, Inc.

Clearbridge BioMedics Pte Ltd., Singapore

Cynvenio Biosystems

Exosome Diagnostics, Inc.

Fluxion Biosciences

Foundation Medicine

Universitätsklinikum Hamburg-Eppendorf

Brooklyn ImmunoTherapeutics, LLC

Ohio State University

Palo Alto Research Center

Rarecells

Silicon Biosystems

The Scripps Research Institute

University of Minnesota

Janssen Diagnostics, LLC

University of Regensburg

Innocrin Pharmaceuticals Inc.

Information provided by (Responsible Party):

Memorial Sloan Kettering Cancer Center

Study Description

Brief Summary:

The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.

Condition or disease
Prostate Cancer

Detailed Description:

The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.

Study Design

Layout table for study information

Study Type :	Observational
Actual Enrollment :	5290 participants
Observational Model:	Case-Only
Time Perspective:	Other
Official Title:	Molecular Studies and Clinical Correlations in Human Prostatic Disease
Study Start Date :	April 1990
Estimated Primary Completion Date :	December 2023
Estimated Study Completion Date :	December 2023

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Prostate cancer

MedlinePlus related topics: Prostate Diseases

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Biospecimen Retention: Samples With DNA

Human tissue, body fluids, and blood Fresh tissue will be obtained from patients undergoing a biopsy or surgical procedure as part of their standard therapy or as part of an investigational research protocol. Previously stored pathology specimens may also be used. Peripheral blood, bone marrow, urine, and other bodily fluids and samples will also be obtained as needed.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	Child, Adult, Older Adult
Sexes Eligible for Study:	Male
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

All patients meeting the eligibility criteria and receiving or seeking prostate cancer treatment in the Genitourinary Oncology/Urology Services will be approached by a consenting professional at a suitable point in their clinical course prior to biospecimen collection.

Criteria

Inclusion Criteria:

Men with prostate conditions representing the following disease states:

No Cancer Diagnosis
Clinically Localized Disease
Rising PSA
Clinical Metastases: Noncastrate
Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml)
Signed informed consent

Exclusion Criteria:

-Patients without any prostate related problems.

Contacts and Locations